Scholar Rock Holding Dirección
Dirección controles de criterios 2/4
El CEO de Scholar Rock Holding es David Hallal , nombrado en Apr 2025, tiene una permanencia de 1.33 años. compensación anual total es $33.30M, compuesta por 1.9% salario y 98.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.33% de las acciones de la empresa, por valor de $21.00M. La antigüedad media del equipo directivo y de la junta directiva es de 2 años y 10.9 años, respectivamente.
Información clave
David Hallal
Chief Executive Officer (CEO)
US$33.3m
Compensación total
| Porcentaje del salario del CEO | 1.91% |
| Permanencia del CEO | 1.3yrs |
| Participación del CEO | 0.3% |
| Permanencia media de la dirección | 2yrs |
| Promedio de permanencia en la Junta Directiva | 10.9yrs |
Actualizaciones recientes de la dirección
Recent updates
SRRK: Regulatory Resubmission And Trial Updates Will Shape Balanced Risk Profile
Scholar Rock Holding's analyst price target has moved higher to $59.31 from $55.07, with analysts pointing to updated assumptions on fair value, profit margin and future P/E as key drivers of the change. Analyst Commentary Recent Street research on Scholar Rock Holding centers on updated price targets and reactions to regulatory milestones, giving you a clearer sense of how analysts are framing valuation, execution risk and potential growth corridors for the company.Scholar Rock: New Treatment Boost For SMA Patients -- With September PDUFA
Summary Scholar Rock Holding Corporation (SRRK) focuses on Apitegromab, a selective anti-latent myostatin antibody for Spinal Muscular Atrophy in patients aged 2 and above. The initial FDA BLA submission for Apitegromab was rejected, but SRRK has since resubmitted its BLA for review. The investment thesis centers on regulatory progress and the clinical potential of Apitegromab in addressing unmet needs in SMA. SRRK's future hinges on successful FDA approval and market adoption of its lead therapy. Read the full article on Seeking AlphaScholar Rock Holding (SRRK) Stock Could Be 14.1% Undervalued On Its SMA Narrative
Scholar Rock Holding (SRRK) stock has drawn investor attention after a recent move in its share price, with the company’s Nasdaq listing closing at $47.33 and showing mixed short and longer term return figures. See our latest analysis for Scholar Rock Holding. For context, Scholar Rock Holding’s recent 1-day share price return of 0.81% and 7-day share price return of 7.13% sit alongside a slightly weaker 30-day share price return, while its 1-year and 3-year total shareholder returns point to...Muscle-Targeted SMA Therapies And Global Expansion Will Reshape Long-Term Outlook
Catalysts About Scholar Rock Holding Scholar Rock Holding focuses on developing muscle-targeted therapies for rare and severe neuromuscular diseases, led by its apitegromab program for spinal muscular atrophy and a broader anti myostatin pipeline. What are the underlying business or industry changes driving this perspective?Scholar Rock: Apitegromab Approval And Obesity Shot Make For Rating Upgrade
Summary Scholar Rock Holding Corporation's lead candidate, apitegromab, has shown promising efficacy in treating SMA and is awaiting FDA and EMA approval, with a potential market launch by late 2025. Apitegromab could achieve blockbuster status with peak revenue potential >$2.5bn, especially based on its ability to build muscle mass in combo with gene therapies like Spinraza and Zolgensma. Scholar Rock's obesity therapy potential with apitegromab and GLP-1 RA combo presents a high-risk, high-reward scenario, with significant upside if Phase 2 data is positive. Despite financial challenges and potential dilution, I upgrade SRRK stock to a "Buy" due to its promising pipeline and undervalued stock price at $30. Read the full article on Seeking AlphaScholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data
Summary Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Apitegromab is being explored in the phase 2 proof-of-concept EMBRAZE study, given alongside GLP-1 drugs to treat patients with obesity; Data from this trial is expected in Q2 of 2025. Positive data from the phase 2 EMBRAZE study would lead to IND of SRK-439 in Q3 of 2025 to target obesity and other cardiometabolic disorders. The global obesity drugs market is expected to reach $200 billion by 2031. Read the full article on Seeking AlphaScholar Rock: Likely Approval In SMA Plus Obesity Data In 2025 Intrigue, But Price Too High
Summary Scholar Rock's lead candidate, apitegromab, showed promising Phase 3 results in SMA, boosting shares by over 325%, with plans for regulatory submissions in the US and EU. Despite positive data, Scholar Rock faces financial challenges, including significant net losses and limited cash, suggesting potential future fundraisings. The company is exploring apitegromab's potential in obesity treatment, with a Phase 2 study underway, in combo with a GLP-1 agonist drug - results are expected in Q2 2025. Given current valuation and financial risks, I recommend a "Hold" rating, with potential buying opportunities post-approval or pre-obesity study results if the share price dips below $30, I'd suggest. Read the full article on Seeking AlphaScholar Rock: SMA Program Strides Forward With Positive Clinical Data
Summary Apitegromab met the primary endpoint in its phase 3 SAPPHIRE study for spinal muscular atrophy, setting up BLA & MAA filings in Q1 2025. Apitegromab is the first treatment targeting muscle fiber atrophy in SMA, potentially changing the standard of care and offering a competitive edge. Scholar Rock also has apitegromab being explored in a phase 2 study for obesity, with clinical data expected in Q2 2025, presenting another catalyst. The spinal muscular atrophy market in the 7 major markets [7MM] is expected to reach $13 billion by 2034. Read the full article on Seeking AlphaScholar Rock: Solid Data And Good Prospects
Summary Scholar Rock's stock price has increased from $6 to $16, indicating increased market interest. Scholar Rock develops apitegromab, a targeted therapy for Spinal Muscular Atrophy (SMA) that inhibits myostatin activation. Phase 2 data shows sustained improvement in motor function for non-ambulatory SMA patients receiving apitegromab. Phase 3 data expected in 4Q 2024. Read the full article on Seeking AlphaAnálisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$409m |
| Mar 31 2026 | n/a | n/a | -US$409m |
| Dec 31 2025 | US$33m | US$638k | -US$378m |
| Sep 30 2025 | n/a | n/a | -US$353m |
| Jun 30 2025 | n/a | n/a | -US$316m |
| Mar 31 2025 | n/a | n/a | -US$264m |
| Dec 31 2024 | US$401k | n/a | -US$246m |
| Sep 30 2024 | n/a | n/a | -US$226m |
| Jun 30 2024 | n/a | n/a | -US$204m |
| Mar 31 2024 | n/a | n/a | -US$183m |
| Dec 31 2023 | US$417k | n/a | -US$166m |
| Sep 30 2023 | n/a | n/a | -US$159m |
| Jun 30 2023 | n/a | n/a | -US$160m |
| Mar 31 2023 | n/a | n/a | -US$166m |
| Dec 31 2022 | US$316k | n/a | -US$135m |
| Sep 30 2022 | n/a | n/a | -US$131m |
| Jun 30 2022 | n/a | n/a | -US$125m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | US$315k | n/a | -US$132m |
| Sep 30 2021 | n/a | n/a | -US$122m |
| Jun 30 2021 | n/a | n/a | -US$109m |
| Mar 31 2021 | n/a | n/a | -US$97m |
| Dec 31 2020 | US$400k | n/a | -US$86m |
| Sep 30 2020 | n/a | n/a | -US$71m |
| Jun 30 2020 | n/a | n/a | -US$64m |
| Mar 31 2020 | n/a | n/a | -US$57m |
| Dec 31 2019 | US$303k | n/a | -US$51m |
Compensación vs. Mercado: La compensación total de David($USD33.30M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD8.22M).
Compensación vs. Ingresos: La compensación de David ha aumentado mientras la empresa no es rentable.
CEO
David Hallal (60 yo)
Mr. David L. Hallal is Chief Executive Officer of Scholar Rock, Inc. since April 27, 2025 and serves as its Chairman of the Board of Directors since July 2017. He had been its Executive Chairman since Apri...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Chairman of the Board | 1.3yrs | US$33.30m | 0.33% $ 21.0m | |
| CFO & Treasurer | 1.3yrs | US$13.12m | 0.039% $ 2.5m | |
| Chief Operating Officer | 1.3yrs | US$13.16m | 0.039% $ 2.5m | |
| President of R&D | 1.3yrs | US$14.89m | 0.048% $ 3.0m | |
| Interim Principal Financial & Accounting Officer | 6.8yrs | sin datos | 0.068% $ 4.3m | |
| Chief Technical & Quality Officer | 1.6yrs | sin datos | sin datos | |
| Chief Scientific Officer | 2.5yrs | US$2.96m | sin datos | |
| Vice President of Corporate Affairs & Investor Relations | no data | sin datos | sin datos | |
| General Counsel & Corporate Secretary | 6.4yrs | US$2.13m | 0.11% $ 6.9m | |
| Chief Human Resources Officer | 5yrs | sin datos | 0.071% $ 4.5m | |
| Senior Vice President of Human Resources | no data | sin datos | sin datos | |
| Senior Vice President of Clinical Development & Operations | 6.4yrs | sin datos | sin datos |
Equipo directivo experimentado: El equipo directivo de SRRK se considera experimentado (2 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Chairman of the Board | 9.1yrs | US$33.30m | 0.33% $ 21.0m | |
| President of R&D | 12.6yrs | US$14.89m | 0.048% $ 3.0m | |
| Independent Director & Member of Scientific Advisory Board | 12.8yrs | US$531.05k | 0.043% $ 2.7m | |
| Member of Scientific Advisory Board | no data | US$48.97k | sin datos | |
| Independent Director & Member of Scientific Advisory Board | 9.8yrs | US$540.66k | 0.017% $ 1.1m | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 12yrs | US$531.05k | 0.089% $ 5.6m | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 5.4yrs | US$540.05k | 0.010% $ 659.9k |
Junta con experiencia: Los miembros de la junta directiva de SRRK son experimentados ( 10.9 años antigüedad media).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/18 12:37 |
| Precio de las acciones al final del día | 2026/08/18 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Scholar Rock Holding Corporation está cubierta por 25 analistas. 16 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Madhu Kumar | Baird |
| Etzer Darout | Barclays |
| Evan Seigerman | BMO Capital Markets Equity Research |